-
What Emerging Class of Agents Should Be Used in Relapsed/Refractory MM Upon Approval? Sagar Lonial, MD, FACP vs. Peter Voorhees, MD vs. Kenneth Anderson, MD #ASH20
29:57
-
Should Antibodies be a Standard Agent Included in Regimens for First Relapse? Sagar Lonial, MD, FACP vs. Kenneth Anderson, MD #ASH20
21:49
-
Panel Discussion and Q&A #ASH20
15:32
-
Transplant vs. No Transplant; Kenneth Anderson vs. Peter Voorhees, MD #ASH20
23:47
-
Is There Sufficient Data to Include Antibodies in Frontline Regimens? Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD #ASH20
25:56
-
Should We be Treating Patients with High-Risk Smoldering MM? Pieter Sonneveld, MD, PhD vs. Peter Voorhees, MD #ASH20
20:39
-
Nina Shah, MD #HemeWorkshop2020
5:16
Nina Shah talks about differences in tumor microenvironment populations and how stimulatory/inhibotory factors can influence how patients respond to immunotherapy, and new BCMA-targeted therapies for myeloma on the horizon.
-
Nikhil Munshi, MD; Sagar Lonial, MD, FACP #HemeWorkshop2020
9:04
Nikhil Munshi talks to Sagar Lonial about the use of antibody-drug conjugate to target BCMA in myeloma.
-
Cesar Rodriguez Valdez, MD; Wake Forest University Comprehensive Cancer Center; 5Live #ASH20
7:20
Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma
-
Deepu Madduri, MD; Mount Sinai Hospital; 5Live #ASH20
2:03
Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma
-
Saad Usmani, MD MBA FACP; Levine Cancer Institute/Atrium Health; 5Live #ASH20
5:46
Key insights from the 2020 Annual Hematology meeting in Multiple Myeloma
- Next Page